On July 20, 2026 Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, reported it will present the latest clinical study results of its novel Nectin‑4‑targeting ADC, 9MW2821, for triple‑negative breast cancer in an oral presentation at the 2026 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Annual Congress in Madrid, Spain, October 23-27, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral Presentation
Title: Bulumtatug Fuvedotin (BFv, 9MW2821), a Nectin-4-Directed Antibody-Drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer (la/mTNBC) Previously Treated with Topoisomerase I Inhibitor (Topl)-Based ADCs: Results from a Phase 2 Study.
Abstract No.: 4640RO
Presenter: Prof. ZHANG Jian, Chief Physician, Doctoral Supervisor (Fudan University Shanghai Cancer Center)
Session: Breast cancer, advanced stage
Session Date and Time: 10/26/2026, 10:15 AM-11:45 AM (local time)
(Press release, Mabwell Biotech, JUL 20, 2026, View Source;mabwell-to-present-latest-clinical-data-on-nectin-4-targeting-adc-9mw2821-for-triple-negative-breast-cancer-in-oral-presentation-302830241.html [SID1234669326])